Effects of Induced Mast Cell Activation on Prostaglandin E and Metalloproteinase Production by Rheumatoid Synovial Tissue in Vitro

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 1998 Apr 16

PMID 9536819

Citations 10

Authors

L C Tetlow

N Harper

T Dunningham

M A Morris

H Bertfield

D E Woolley

Affiliations

Soon will be listed here.

Abstract

Objective: To determine whether induced mast cell activation/degranulation in rheumatoid synovial explants modulates the production of prostaglandin E (PGE2), and the matrix metalloproteinases (MMPs) collagenase 1, gelatinase A, and stromelysin 1.

Methods: Synovial explant cultures were treated either with rabbit IgG anti-human IgE as a mast cell (MC) secretagogue or with non-immune rabbit IgG as controls. After 20 hours conditioned medium was assayed for the release of MC tryptase, PGE2, collagenase 1, gelatinase A, and stromelysin 1 using radioimmunoassay, enzyme linked immunosorbent assay, western blot, and zymogram techniques; tissue explants were examined immunohistologically for the relative distributions of MC tryptase, collagenase 1, and stromelysin 1.

Results: Over a 20 hour incubation period the MC secretagogue treated explants showed a significant increase in the quantities of released tryptase and PGE2 compared with controls. By contrast, the three MMPs showed variable values between experiments in response to MC activation; no reproducible trend of either an increased or decreased production of each MMP over control values was evident. Each MMP initially appeared as an inactive precursor form; collagenase 1 and stromelysin 1 were more effectively processed to active forms in the MC activated cultures. Immunolocalisation studies of MC activated explants showed that areas of extracellular tryptase were commonly associated with the local production of both collagenase 1 and stromelysin 1.

Conclusion: MC degranulation induced artificially in rheumatoid synovial explant cultures consistently resulted in an increased production of PGE2 but had variable effects on the quantification of released collagenase 1, gelatinase A, and stromelysin 1. Such observations support the concept that activated synovial MCs within their native environment stimulate the production of non-MC derived PGE2 and may contribute to the regulation and processing of specific MMPs; both aspects represent important components of the inflammatory and degradative processes of the rheumatoid lesion.

Citing Articles

Roles of mast cells in rheumatoid arthritis.

Min H, Kim K, Lee S, Kim H Korean J Intern Med. 2019; 35(1):12-24.

PMID: 31722515 PMC: 6960056. DOI: 10.3904/kjim.2019.271.

Vascular Contributions to Migraine: Time to Revisit?.

Mason B, Russo A Front Cell Neurosci. 2018; 12:233.

PMID: 30127722 PMC: 6088188. DOI: 10.3389/fncel.2018.00233.

Simulated airplane headache: a proxy towards identification of underlying mechanisms.

Dinh Bui S, Petersen T, Poulsen J, Gazerani P J Headache Pain. 2017; 18(1):9.

PMID: 28130626 PMC: 5272852. DOI: 10.1186/s10194-017-0724-3.

Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage.

Lindsberg P, Strbian D, Karjalainen-Lindsberg M J Cereb Blood Flow Metab. 2010; 30(4):689-702.

PMID: 20087366 PMC: 2949160. DOI: 10.1038/jcbfm.2009.282.

Mast cells as a target in the treatment of rheumatoid arthritis.

Bakharevski O, Ryan P Inflammopharmacology. 2007; 7(4):351-62.

PMID: 17657438 DOI: 10.1007/s10787-999-0029-5.

References

Wu J, Lark M, Chun L, Eyre D . Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J Biol Chem. 1991; 266(9):5625-8. View

Murphy G, Docherty A, Hembry R, Reynolds J . Metalloproteinases and tissue damage. Br J Rheumatol. 1991; 30 Suppl 1:25-31. View

Bridges A, Malone D, Jicinsky J, Chen M, Ory P, Engber W . Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and antirheumatic therapy. Arthritis Rheum. 1991; 34(9):1116-24. DOI: 10.1002/art.1780340907. View

Galli S, Gordon J, Wershil B . Cytokine production by mast cells and basophils. Curr Opin Immunol. 1991; 3(6):865-72. DOI: 10.1016/s0952-7915(05)80005-6. View

Chu C, Field M, Allard S, Abney E, Feldmann M, Maini R . Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol. 1992; 31(10):653-61. DOI: 10.1093/rheumatology/31.10.653. View

Galli S . New concepts about the mast cell. N Engl J Med. 1993; 328(4):257-65. DOI: 10.1056/NEJM199301283280408. View

Birkedal-Hansen H, Moore W, Bodden M, Windsor L, DeCarlo A, Engler J . Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993; 4(2):197-250. DOI: 10.1177/10454411930040020401. View

Schwartz L . Mast cells: function and contents. Curr Opin Immunol. 1994; 6(1):91-7. DOI: 10.1016/0952-7915(94)90039-6. View

Lees M, Taylor D, Woolley D . Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinases A and B. Eur J Biochem. 1994; 223(1):171-7. DOI: 10.1111/j.1432-1033.1994.tb18980.x. View

10.

Suzuki K, Lees M, Newlands G, Nagase H, Woolley D . Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. Biochem J. 1995; 305 ( Pt 1):301-6. PMC: 1136463. DOI: 10.1042/bj3050301. View

11.

Arend W, Dayer J . Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 1995; 38(2):151-60. DOI: 10.1002/art.1780380202. View

12.

Bonassar L, Frank E, Murray J, Paguio C, Moore V, Lark M . Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum. 1995; 38(2):173-83. DOI: 10.1002/art.1780380205. View

13.

Tetlow L, Lees M, Woolley D . Comparative studies of collagenase and stromelysin-1 expression by rheumatoid synoviocytes in vitro. Virchows Arch. 1995; 425(6):569-76. DOI: 10.1007/BF00199344. View

14.

Wooley D . Mast cells in the rheumatoid lesion--ringleaders or innocent bystanders?. Ann Rheum Dis. 1995; 54(7):533-4. PMC: 1009925. DOI: 10.1136/ard.54.7.533. View

15.

Tetlow L, Woolley D . Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion. Ann Rheum Dis. 1995; 54(7):549-55. PMC: 1009933. DOI: 10.1136/ard.54.7.549. View

16.

Tetlow L, Woolley D . Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann Rheum Dis. 1995; 54(11):896-903. PMC: 1010040. DOI: 10.1136/ard.54.11.896. View

17.

Jeziorska M, Salamonsen L, Woolley D . Mast cell and eosinophil distribution and activation in human endometrium throughout the menstrual cycle. Biol Reprod. 1995; 53(2):312-20. DOI: 10.1095/biolreprod53.2.312. View

18.

Verbsky J, McAllister P, Malone D . Mast cell activation in human synovium explants by calcium ionophore A23187, compound 48/80, and rabbit IgG anti-human IgE, but not morphine sulfate. Inflamm Res. 1996; 45(1):35-41. DOI: 10.1007/BF02263503. View

19.

De Paulis A, Ciccarelli A, MARINO I, de Crescenzo G, Marino D, Marone G . Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. Arthritis Rheum. 1997; 40(3):469-78. DOI: 10.1002/art.1780400313. View

20.

Gotis-Graham I, McNeil H . Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum. 1997; 40(3):479-89. DOI: 10.1002/art.1780400314. View